 |
The Journal of the Japanese Society for Clinical Microbiology |
Biblioraphy Information
| ArticleTitle |
Whole-genome sequencing and molecular epidemiology of extended-spectrum β-lactamase-non-producing fluoroquinolone-resistant Escherichia coli |
| Language |
J |
| AuthorList |
Kimitoshi Yoshimura1), Yasufumi Matsumura2,3), Masaki Yamamoto2,3), Miki Nagao2,3) |
| Affiliation |
1) Department of Clinical Laboratory, Saiseikai Noe Hospital
2) Department of Infection Control and Prevention, Kyoto University Hospital
3) Department of Clinical Laboratory Medicine, Kyoto University Graduate School of Medicine |
| Publication |
J.J.C.M.: 35 (2), 144-149, 2025 |
| Received |
January 8, 2025 |
| Accepted |
February 17, 2025 |
| Abstract |
Infections due to fluoroquinolone-resistant Escherichia coli is increasing. Clonal expansion of fluoroquinolone-resistant ST131 is responsible for the increase in extended-spectrum β-lactamase (ESBL)-producing E. coli, whereas data on non-ESBL-producing fluoroquinolone-resistant E. coli are limited. To analyze the molecular epidemiology and fluoroquinolone resistance mechanisms of non-ESBL-producing fluoroquinolone-resistant E. coli, we performed whole-genome sequencing of 124 clinical isolates between 2018 and 2021 at an acute-care hospital in Osaka, Japan. The study isolates were classified into 12 sequence types (STs), with ST131 (59%) and ST1193 (30%) accounting for the majority. The most common ST131 clade was C1-non-M27. All ST131 isolates had four mutations (LNIV pattern) and all ST1193 strains had three mutations (LNIE pattern) in the quinolone resistance determinant regions. Whole-genome analysis of non-ESBL-producing fluoroquinolone-resistant E. coli revealed a molecular epidemiology similar to that of ESBL-producing strains, with the growth of two pandemic clones, ST131 and ST1193, carrying characteristic QRDR mutations. These results suggest a need to strengthen the molecular epidemiological analysis of fluoroquinolone-resistant E. coli in Japan to contribute to the fight against drug-resistant bacteria. |
| Keywords |
ST131, ST1193, QRDR |
|
